A Speculative Stock For What May Be “The Next Big Thing To Sweep Through Biotech”
The company discussed in today’s article is a potential leader in a burgeoning field that the author declares “has the potential to revolutionize medicine in…
The company discussed in today’s article is a potential leader in a burgeoning field that the author declares “has the potential to revolutionize medicine in…
The FDA’s approval of Biogen’s Alzheimer’s drug “has set a precedent, showing a much easier path to approval for investigative drug treatments focused on neurodegenerative…
“These are four quality stocks to buy that have value characteristics but also appear to have the hidden potential to have momentum stock upside,” says…
When it comes to the three biotech stocks discussed in today’s article, all of which are down 45% or more from their 52-week highs, should…
Amid the ongoing opioid crisis, the need for non-opioid pain management solutions is increasing. As a provider of pre- and post-surgical non-opioid pain management solutions,…
When it comes to insider buying, the author of today’s article notes that “Conventional wisdom says that insiders and 10% owners really only buy shares…
With a potential blockbuster drug in its pipeline that would also be the first new therapy for Alzheimer’s disease in decades, the stock featured in…
While the broader market has been all over the place over the past few months, one area that has performed significantly better than the S&P…
Although it was only the 7th worst daily return since 1950, the author of today’s article declares that, for many, March 9, 2020 was the…
It’s the favorite performance chart of the author of today’s article: an “asset allocation quilt” that shows the returns (and respective rankings) for each asset…